An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Allergan
- 23 Jan 2017 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.
- 23 Jan 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Feb 2020.
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.